G6PD and Parkinson disease: In contrast to the findings in human patients, several animal models of PD, including those based on intranigral and intraperitoneal injections of lipopolysaccharide (LPS), MPTP exposure, or A53T α-synuclein transgenics, showed increased G6PD expression and activity (Tu et al., 2019).